Drug intelligence / Profile preview

PBAT-001

Development stage: Preclinical
Lead developer: Novartis
Modality: Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PBAT-001 is a preclinical allogeneic CAR T-cell therapy being developed by Novartis and Precision BioSciences for the treatment of multiple myeloma. It utilizes Precision BioSciences' proprietary ARCUS gene editing platform to engineer T cells, aiming to create scalable, 'off-the-shelf' therapies. The ARCUS platform allows for precise gene editing, including the disruption of endogenous T cell receptors and the insertion of chimeric antigen receptor (CAR) transgenes, to enable the modified T cells to target cancer cells.

Beyond the preview

Go deeper on PBAT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBAT-001.

Explore the full profile